Loading clinical trials...
Loading clinical trials...
Asthma is a significant public health threat, affecting more than 300 million individuals globally. Asthma is classified as a non-communicable disease and leads to reduced quality of life, poor physical functioning and reduced emotional well-being. The impact of this disease can be widespread and extends beyond the person living with the disease, affecting the lives of their family members, carers, communities and the health care system (1). Asthma is a variable chronic respiratory condition. It is characterized by symptoms of wheeze, cough, chest tightness, dyspnea and backed by variable airflow limitation, airway inflammation and airway hyper-responsiveness (AHR). The severity of asthma varies considerably, both between individuals and within individuals over time. Some people may have intermittent asthma and others may experience severe, potentially life-threatening disease (2, 3,4).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Sohag University hospitals
Sohag, Egypt
Start Date
November 1, 2023
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2024
Last Updated
November 21, 2023
200
ESTIMATED participants
corticosteroids
DRUG
Kamal A Atta, Professor
CONTACT
Lead Sponsor
Sohag University
NCT06624735
NCT07054034
NCT06154304
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions